233 related articles for article (PubMed ID: 31869450)
1. The emerging role of mediator complex subunit 12 in tumorigenesis and response to chemotherapeutics.
Zhang S; O'Regan R; Xu W
Cancer; 2020 Mar; 126(5):939-948. PubMed ID: 31869450
[TBL] [Abstract][Full Text] [Related]
2. Insights into the regulatory role and clinical relevance of mediator subunit, MED12, in human diseases.
Srivastava S; Kulshreshtha R
J Cell Physiol; 2021 May; 236(5):3163-3177. PubMed ID: 33174211
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.
Park MJ; Shen H; Spaeth JM; Tolvanen JH; Failor C; Knudtson JF; McLaughlin J; Halder SK; Yang Q; Bulun SE; Al-Hendy A; Schenken RS; Aaltonen LA; Boyer TG
J Biol Chem; 2018 Mar; 293(13):4870-4882. PubMed ID: 29440396
[TBL] [Abstract][Full Text] [Related]
4. Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.
Kämpjärvi K; Kim NH; Keskitalo S; Clark AD; von Nandelstadh P; Turunen M; Heikkinen T; Park MJ; Mäkinen N; Kivinummi K; Lintula S; Hotakainen K; Nevanlinna H; Hokland P; Böhling T; Bützow R; Böhm J; Mecklin JP; Järvinen H; Kontro M; Visakorpi T; Taipale J; Varjosalo M; Boyer TG; Vahteristo P
Prostate; 2016 Jan; 76(1):22-31. PubMed ID: 26383637
[TBL] [Abstract][Full Text] [Related]
5. MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling.
Huang S; Hölzel M; Knijnenburg T; Schlicker A; Roepman P; McDermott U; Garnett M; Grernrum W; Sun C; Prahallad A; Groenendijk FH; Mittempergher L; Nijkamp W; Neefjes J; Salazar R; Ten Dijke P; Uramoto H; Tanaka F; Beijersbergen RL; Wessels LF; Bernards R
Cell; 2012 Nov; 151(5):937-50. PubMed ID: 23178117
[TBL] [Abstract][Full Text] [Related]
6. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas.
Mäkinen N; Mehine M; Tolvanen J; Kaasinen E; Li Y; Lehtonen HJ; Gentile M; Yan J; Enge M; Taipale M; Aavikko M; Katainen R; Virolainen E; Böhling T; Koski TA; Launonen V; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
Science; 2011 Oct; 334(6053):252-5. PubMed ID: 21868628
[TBL] [Abstract][Full Text] [Related]
7. Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
Kämpjärvi K; Park MJ; Mehine M; Kim NH; Clark AD; Bützow R; Böhling T; Böhm J; Mecklin JP; Järvinen H; Tomlinson IP; van der Spuy ZM; Sjöberg J; Boyer TG; Vahteristo P
Hum Mutat; 2014 Sep; 35(9):1136-41. PubMed ID: 24980722
[TBL] [Abstract][Full Text] [Related]
8. The novel mechanism of Med12-mediated drug resistance in a TGFBR2-independent manner.
Han Y; Dong Q; Liu T; Chen X; Yu C; Zhang Y
Biochem Biophys Res Commun; 2022 Jun; 610():1-7. PubMed ID: 35461070
[TBL] [Abstract][Full Text] [Related]
9. MED12 mutations in human diseases.
Wang H; Shen Q; Ye LH; Ye J
Protein Cell; 2013 Sep; 4(9):643-6. PubMed ID: 23836153
[TBL] [Abstract][Full Text] [Related]
10. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.
Turunen M; Spaeth JM; Keskitalo S; Park MJ; Kivioja T; Clark AD; Mäkinen N; Gao F; Palin K; Nurkkala H; Vähärautio A; Aavikko M; Kämpjärvi K; Vahteristo P; Kim CA; Aaltonen LA; Varjosalo M; Taipale J; Boyer TG
Cell Rep; 2014 May; 7(3):654-60. PubMed ID: 24746821
[TBL] [Abstract][Full Text] [Related]
11. MED12 exerts an emerging role in actin-mediated cytokinesis via LIMK2/cofilin pathway in NSCLC.
Xu M; Wang F; Li G; Wang X; Fang X; Jin H; Chen Z; Zhang J; Fu L
Mol Cancer; 2019 May; 18(1):93. PubMed ID: 31072327
[TBL] [Abstract][Full Text] [Related]
12. Loss of MED12 Induces Tumor Dormancy in Human Epithelial Ovarian Cancer via Downregulation of EGFR.
Luo XL; Deng CC; Su XD; Wang F; Chen Z; Wu XP; Liang SB; Liu JH; Fu LW
Cancer Res; 2018 Jul; 78(13):3532-3543. PubMed ID: 29735544
[TBL] [Abstract][Full Text] [Related]
13. Mediator kinase module and human tumorigenesis.
Clark AD; Oldenbroek M; Boyer TG
Crit Rev Biochem Mol Biol; 2015; 50(5):393-426. PubMed ID: 26182352
[TBL] [Abstract][Full Text] [Related]
14. NEAT1 repression by MED12 creates chemosensitivity in p53 wild-type breast cancer cells.
Zhang S; Kim EJ; Huang J; Liu P; Donahue K; Wang Q; Wang Y; Mcilwain S; Xie L; Chen X; Li L; Xu W
FEBS J; 2024 May; 291(9):1909-1924. PubMed ID: 38380720
[TBL] [Abstract][Full Text] [Related]
15. MED12 somatic mutations encompassing exon 2 associated with benign breast fibroadenomas and not breast carcinoma in Indian women.
Darooei M; Khan F; Rehan M; Zubeda S; Jeyashanker E; Annapurna S; Shah A; Maddali S; Hasan Q
J Cell Biochem; 2019 Jan; 120(1):182-191. PubMed ID: 30230586
[TBL] [Abstract][Full Text] [Related]
16. Mediator kinase module proteins, genetic alterations and expression of super-enhancer regulated genes in colorectal cancer.
Voutsadakis IA
Pharmacol Rep; 2024 Jun; 76(3):535-556. PubMed ID: 38602606
[TBL] [Abstract][Full Text] [Related]
17. A precisely positioned MED12 activation helix stimulates CDK8 kinase activity.
Klatt F; Leitner A; Kim IV; Ho-Xuan H; Schneider EV; Langhammer F; Weinmann R; Müller MR; Huber R; Meister G; Kuhn CD
Proc Natl Acad Sci U S A; 2020 Feb; 117(6):2894-2905. PubMed ID: 31988137
[TBL] [Abstract][Full Text] [Related]
18. MED12 is overexpressed in glioblastoma patients and serves as an oncogene by targeting the VDR/BCL6/p53 axis.
Srivastava S; Makala H; Sharma V; Suri V; Sarkar C; Kulshreshtha R
Cell Mol Life Sci; 2022 Jan; 79(2):104. PubMed ID: 35091793
[TBL] [Abstract][Full Text] [Related]
19. RISING STARS: Role of MED12 mutation in the pathogenesis of uterine fibroids.
Ishikawa H; Kobayashi T; Kaneko M; Saito Y; Shozu M; Koga K
J Mol Endocrinol; 2023 Nov; 71(4):. PubMed ID: 37668348
[TBL] [Abstract][Full Text] [Related]
20. Mediator subunit Med12 contributes to the maintenance of neural stem cell identity.
Kim NH; Livi CB; Yew PR; Boyer TG
BMC Dev Biol; 2016 May; 16(1):17. PubMed ID: 27188461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
